Physician profile
Marie E Dilascio
NPI 1457851347
$5,746.72
in general payments reported to CMS, 2019-2025
25 companies · $2,054 in 2025
The $2,054 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,048 · 2024: $2,645 · 2025: $2,054.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,506 · Education: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,505.50 |
| Education | $241.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $759.64 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $574.42 | 2023-2025 | Sotyktu |
| Janssen Biotech, INC. | $565.47 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Amgen INC. | $498.69 | 2023-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $483.98 | 2023-2025 | Dupixent |
| Ucb, INC. | $443.76 | 2023-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $375.46 | 2023-2025 | |
| Abbvie INC. | $361.66 | 2023-2025 | |
| Incyte Corporation | $279.11 | 2023-2025 | Opzelura |
| Biofrontera INC. | $261.20 | 2023-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Lilly USA, LLC | $258.57 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $170.01 | 2024-2025 | Nemluvio |
| Pfizer INC. | $133.01 | 2024 | |
| Arcutis Biotherapeutics, INC. | $113.92 | 2024-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.69 | 2023-2025 | Spevigo, Cyltezo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $79.99 | 2023 | |
| Organogenesis INC. | $57.99 | 2024 | |
| Fresenius Kabi USA, LLC | $51.66 | 2023-2024 | Idacio |
| Leo Pharma INC. | $51.40 | 2025 | Adbry |
| Mayne Pharma Commercial LLC | $40.74 | 2025 | |
| Verrica Pharmaceuticals INC. | $33.75 | 2024-2025 | Ycanth |
| Organon LLC | $24.54 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.71 | 2024 | Arazlo |
| Sun Pharmaceutical Industries INC. | $14.56 | 2025 | |
| Dermavant Sciences, INC. | $13.79 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marie Dilascio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.